News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 10 - 09

Core Medical's Corheart 6 Tops 1,000 Implants, Setting New Global Standard

Recently, Shenzhen Core Medical Technology Co., Ltd. announced that its flagship product, the Corheart® 6 implantable left ventricular assist system (implantable artificial heart), has completed its 1,000th implantation. This makes it the world's second third-generation fully magnetically levitated artificial heart (after Abbott's HeartMate 3, launched in 2015) and the first such domestically produced device to surpass the 1,000-case milestone.As the latest domestic product to enter the market but the first to reach 1,000 implantations, Corheart® 6 secured over 50% market sha...

浏览次数：1

查看详情>>

发布时间: 2025 - 10 - 06

The 2025 Nobel Prize in Physiology or Medicine Announced!

On October 6, local time, the annual Nobel Prize "award week" kicked off, with six prizes to be announced one by one. Among them, three scientists—Mary E. Brunkow, Fred Ramsdell, and Shimon Sakaguchi—were awarded the 2025 Nobel Prize in Physiology or Medicine.Over its century-long history, the Nobel Prize has been awarded 627 times. Winners of prizes in Physiology or Medicine, Physics, Chemistry, and other categories typically receive a medal, a diploma, and a substantial monetary award.01 Nobel's Will and Its Century-Long Resonance"Convert my entire remaining estate into a ...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 30

Monthly Health Read | September 2025

n the first half of 2025, the National Medical Products Administration (NMPA) approved 53 new chemical drugs, representing a 43% increase compared to the same period in 2024. Among them, 27 were innovative chemical drugs.This impressive achievement not only reflects the strength of China's pharmaceutical innovation but also serves as the best validation for forward-looking investors. Amid this surging wave of innovation, Efung Capital and its partner pharmaceutical companies have added a brilliant chapter to this remarkable scorecard with their outstanding performance.01 Portfolio Company ...

浏览次数：1

查看详情>>

发布时间: 2025 - 09 - 30

Genuine Biotech's GEN-725 + Doxitinib Mesylate Approved for Clinical Trial

On September 29, 2025, Henan Genuine Biotech Co., Ltd. announced that its self-developed anti-tumor drug GEN-725 in combination with doxitinib mesylate has received approval from the National Medical Products Administration (NMPA) to conduct clinical trials in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring EGFR mutations.GEN-725 is an anti-tumor drug developed by Henan Genuine Biotech Co., Ltd. with independent intellectual property rights. Systematic studies have revealed that GEN-725 exerts its anti-tumor effects through a dual mechanism: (1) as a n...

浏览次数：1

查看详情>>